Statement: FDA Must Reject Tanezumab as a Treatment for Osteoarthritis Due to Unacceptable Dangers, Little to No Benefit
Energy Future Holdings $1 Billion Bonding for Texas Mines Doesn’t Pass the Smell Test October 16, 2013